Crinetics Pharmaceuticals Files 8-K

Ticker: CRNX · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1658247

Crinetics Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyCrinetics Pharmaceuticals, Inc. (CRNX)
Form Type8-K
Filed DateJun 3, 2024
Risk Levellow
Pages4
Reading Time4 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-disclosure, 8-K

Related Tickers: CRNX

TL;DR

CRNX filed an 8-K confirming its HQ and Nasdaq listing.

AI Summary

On June 3, 2024, Crinetics Pharmaceuticals, Inc. (CRNX) filed an 8-K report. The filing confirms the company's principal executive offices are located at 6055 Lusk Boulevard, San Diego, California, 92121. Crinetics Pharmaceuticals, Inc. is registered in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol CRNX.

Why It Matters

This 8-K filing serves as a routine update, confirming basic corporate information and stock exchange listing for Crinetics Pharmaceuticals.

Risk Assessment

Risk Level: low — This filing is a standard corporate disclosure and does not contain material non-public information that would typically impact risk.

Key Players & Entities

  • Crinetics Pharmaceuticals, Inc. (company) — Registrant
  • June 3, 2024 (date) — Date of earliest event reported
  • 6055 Lusk Boulevard, San Diego, California, 92121 (location) — Address of Principal Executive Offices
  • CRNX (ticker) — Trading Symbol for Common Stock
  • Nasdaq Global Select Market (exchange) — Exchange where Common Stock is registered

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information as required by the SEC, specifically confirming the registrant's details and principal executive offices.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on June 3, 2024.

Where are Crinetics Pharmaceuticals, Inc.'s principal executive offices located?

Crinetics Pharmaceuticals, Inc.'s principal executive offices are located at 6055 Lusk Boulevard, San Diego, California, 92121.

On which stock exchange is Crinetics Pharmaceuticals, Inc. common stock traded?

Crinetics Pharmaceuticals, Inc. common stock is traded on the Nasdaq Global Select Market.

What is the trading symbol for Crinetics Pharmaceuticals, Inc. common stock?

The trading symbol for Crinetics Pharmaceuticals, Inc. common stock is CRNX.

Filing Stats: 1,054 words · 4 min read · ~4 pages · Grade level 11.5 · Accepted 2024-06-03 16:35:07

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this report are forward-looking statements. These forward-looking statements speak only as of the date of this report and are subject to a number of known and unknown risks, uncertainties and assumptions, including, without limitation, the risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission ("SEC"). The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading "Risk Factors" in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2023 and quarterly report on Form 10-Q for the quarter ended March 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Item9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated June 3, 2024. 99.2 Press Release dated June 3, 2024. 99.3 Corporate Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date:June 3, 2024 By: /s/ R. Scott Struthers, Ph.D. R. Scott Struthers, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.